The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy for treating women with hormone receptor-positive cancer suppresses breast cancer growth either by reducing estrogen synthesis or by interfering with the action of estrogen within tumor cells. In this prospective randomized observational study we investigate the effect of adjuvant anastrozole in monotherapy or associated with risedronate on bone physiology and quality of life in postmenopausal, hormone-sensitive early breast cancer women at mild to moderate risk of fragility fractures. Methods : 84 women were randomly assigned to receive anastrozole alone (group A) or anastrozole plus oral risedronate (group A+R). At baseline and after 24 mo...
Our objective was to assess the impact of treatment with risedronate on the bone mineral density and...
AbstractPurposeThe ARIBON trial is a double blind, randomised, placebo controlled study designed to ...
Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sec...
The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy...
The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy...
The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with ris...
The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with ris...
Purpose To investigate the management of bone health in women with early breast cancer (EBC) who wer...
Background: Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the d...
SummaryBackgroundAromatase inhibitors prevent breast cancer in postmenopausal women at high risk of ...
The role of aromatase inhibitors (AIs) in breast cancer has expanded since their introduction in the...
Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of...
The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmen...
AbstractPostmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associa...
Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA...
Our objective was to assess the impact of treatment with risedronate on the bone mineral density and...
AbstractPurposeThe ARIBON trial is a double blind, randomised, placebo controlled study designed to ...
Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sec...
The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy...
The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy...
The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with ris...
The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with ris...
Purpose To investigate the management of bone health in women with early breast cancer (EBC) who wer...
Background: Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the d...
SummaryBackgroundAromatase inhibitors prevent breast cancer in postmenopausal women at high risk of ...
The role of aromatase inhibitors (AIs) in breast cancer has expanded since their introduction in the...
Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of...
The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmen...
AbstractPostmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associa...
Treatment of breast cancer with aromatase inhibitors is associated with damage to bones. NCIC CTG MA...
Our objective was to assess the impact of treatment with risedronate on the bone mineral density and...
AbstractPurposeThe ARIBON trial is a double blind, randomised, placebo controlled study designed to ...
Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sec...